MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

Keyphrases

• T-cell Acute Lymphoblastic Leukemia (T-ALL) 100%
• Receptor Signaling 100%
• IL-7 Receptor 100%
• AKT1 100%
• AKT Inhibitor 100%
• Signaling Molecules 66%
• MEK-ERK 66%
• PI3K-Akt Pathway 66%
• Pediatric 33%
• Dual Inhibition 33%
• Leukemia 33%
• Therapeutic Potential 33%
• Signaling Pathway 33%
• Xenograft Model 33%
• Downstream Signaling 33%
• Leukemia Patients 33%
• Downstream Targets 33%
• Cytotoxic Effect 33%
• Mutually Exclusive 33%
• Janus Kinase 1 (JAK1) 33%
• Primary T Cells 33%
• JAK3 33%
• IL-7R 33%
• K-ras 33%
• JAK Inhibitors 33%
• N-Ras 33%
• PI3K-AKT-mTOR Pathway 33%
• STAT5A 33%
• BaF3 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Acute Lymphoblastic Leukemia 100%
• Leukemia 33%
• Janus Kinase Inhibitor 33%
• Cytotoxicity 33%

Biochemistry, Genetics and Molecular Biology

• T Cell 100%
• Wild Type 33%
• Signal Transduction 33%
• Cytotoxicity 33%
• Janus Kinase Inhibitor 33%
• PI3K/AKT/mTOR Pathway 33%
• STAT5B 33%